Bloomberg - Tekturna, Exforge, Exjade for removing excess iron, the Lucentis eye treatment and the Xolair asthma drug had combined sales of $300 million in the quarter. Sales of Diovan, the heart treatment that's the company's best-seller, rose 16 percent to $1 ...
